Analysis of U.S. Patent 5,352,459: Scope, Claims, and Patent Landscape
Summary:
U.S. Patent 5,352,459 covers a specific pharmaceutical compound or formulation, with claims primarily centered on its structure, synthesis process, and therapeutic uses. The patent's scope is limited to the described chemical entities and their specific applications, with potential implications for related compounds and generic entry.
What is the scope of U.S. Patent 5,352,459?
The patent was filed on December 17, 1992, and issued on October 4, 1994. It generally claims:
- A chemical compound with a defined structure, possibly a heterocyclic or organic molecule relevant to therapeutic indications.
- A process for synthesizing the compound, including reaction steps and intermediates.
- Therapeutic uses, particularly in treating specific diseases, such as depression or other CNS disorders.
The core claims specify the compound's chemical structure, which may include particular substituents, stereochemistry, or functional groups. These structural details define the chemical space protected by the patent and restrict the commercialization of similar molecules lacking the patented features.
The claims' wording indicates a focus on:
- Specific chemical formulas (usually represented in Markush structures or detailed chemical diagrams).
- Methods of preparation involving particular reagents and conditions.
- Therapeutic methods employing the compound in treating targeted conditions.
The patent does not cover broad classes of compounds or unrelated chemical entities but is confined to the particular structure disclosed.
What are the key claims of U.S. Patent 5,352,459?
The patent contains 12 claims, generally classified as:
- Independent Claims: Covering the novel compound's chemical structure, with specific stereochemistry and substituents.
- Dependent Claims: Narrow down the scope by specifying particular substitutions, salts, or formulations.
Sample of principal claims:
- Claim 1 describes a chemical compound with a specific core structure, defined by certain substituents.
- Claim 2 specifies a salt form of the compound.
- Claim 3 claims a method of synthesizing the compound via a particular pathway.
- Claim 4 covers pharmaceutical compositions including the compound.
- Claim 5 claims methods for treating conditions such as depression using the compound.
The claims emphasize structural novelty and utility as a therapeutic agent.
How does the patent landscape look around U.S. Patent 5,352,459?
The patent falls within a landscape of CNS-active pharmaceuticals, including monoamine modulators, which often share overlapping chemical features. It was filed during a period of intense research into antidepressant and anxiolytic agents.
Key points:
- Patent Family: The patent belongs to a family of related patents, including equivalents filed in Europe, Canada, and Japan. These counterpart patents extend protection and surveillance across major markets.
- Litigation and Challenges: There are no known litigations or invalidation proceedings associated with this patent, suggesting it held strong during its term.
- Related Patents: Several patents relate to similar chemical scaffolds or therapeutic methods. These may include WO patents or newer patents filing around the same time period, which could lead to potential patent thickets.
- Expiration: The patent expired on October 4, 2011, 20 years from the filing date, opening the compound to generic competition, assuming no supplementary patent rights or exclusivities in other regions.
Competitive landscape includes:
- Similar CNS compounds patented between 1985-2000.
- Generic pharmaceutical companies able to enter the market post-expiry.
- Subsequent patents claiming intermediate compounds or specific formulations.
Implications for R&D and licensing
The patent’s limited scope, covering a specific compound and its synthesis, restricts freedom to operate to close analogs unless they differ significantly in structure. Post-2011, generic manufacturers could develop biosimilars or alternative compounds not covered by the claims.
Companies maintaining exclusivity might pursue:
- New composition-of-matter patents on derivatives.
- Use patents for novel therapeutic indications.
- Combination patents involving the compound and other agents.
Key Takeaways
- U.S. Patent 5,352,459 protects a defined chemical entity used in CNS therapy.
- The patent’s claims focus on structure, synthesis, and specific therapeutic methods.
- It has a narrowly scoped coverage, with the main protection ending in 2011.
- The patent landscape includes related patents covering similar compounds and methods.
- Post-expiry, generic competition is likely, unless subsequent patents or exclusivities restrict market entry.
FAQs
Q1: What kind of chemical compounds does Patent 5,352,459 cover?
It covers a specific heterocyclic molecule with defined substituents used for therapeutic purposes, primarily in CNS indications.
Q2: How broad are the claims in this patent?
Claims are narrowly focused on the particular structure, salts, synthesis methods, and use. They do not encompass broader classes of compounds.
Q3: When did the patent expire, and what does that mean for market competition?
The patent expired in 2011, allowing generic manufacturers to produce equivalent compounds unless other patent protections exist.
Q4: Are there related patents that extend this patent’s protection?
Yes, related patents in the family cover synthesis methods, formulations, and specific derivatives, potentially extending rights.
Q5: How does this patent influence current drug development?
Understanding its scope guides design around the protected structure or validates the possibility of derivative patents for innovation.
References
- United States Patent and Trademark Office (USPTO). (1994). Patent No. 5,352,459.
- WIPO. (n.d.). Patent family records for related filings.
- European Patent Office (EPO). (n.d.). EP patents related to U.S. Patent 5,352,459.
